NCT01390792已完成不适用
Special Drug Use Investigation for Relenza® (Zanamivir) (Prophylaxis)
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 622
- 主要终点
- The number of incidence of adverse events in subjects treated with zanamivir
研究概览
简要总结
The purpose of this post-marketing surveillance study is to collect information on efficacy and safety for prophylactic administration of zanamivir in clinical practice in family or persons living with patients with influenza virus infection.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects who meet the study population criteria
排除标准
- •Subjects with a history of hypersensitivity to the ingredients of zanamivir
研究组 & 干预措施
Subjects prescribed zanamivir
Subjects prescribed zanamivir during study period
干预措施: Zanamivir hydrate (Drug)
结局指标
主要结局
The number of incidence of adverse events in subjects treated with zanamivir
时间窗: 11 days
Occurrence of influenza virus infection
时间窗: 11 days
次要结局
未报告次要终点
研究者
相似试验
已完成
不适用
Special Drug Use Investigation (Retrospective) for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment (Over 100kg)AtaxiaNCT01428544GlaxoSmithKline5
已完成
不适用
Drug Use Investigation for XYZAL®Rhinitis, Allergic, Perennial and SeasonalNCT01445262GlaxoSmithKline10,728
已完成
不适用
Special Drug Use Investigation for Arixtra® (Fondaparinux) Venous Thromboembolism TreatmentAtaxiaNCT01428531GlaxoSmithKline200
已完成
4 期
A Study of Tadalafil (LY450190) in Chinese Men With Erectile DysfunctionErectile DysfunctionNCT02224846Eli Lilly and Company635
已完成
不适用
Special Drug Use Investigation for VALTREX (Valaciclovir) (Pediatrics Chickenpox)VaricellaNCT01390857GlaxoSmithKline379